Cancer Patient Perspectives Panel at 2019 CRI Immunotherapy Patient Summit in NYC скачать в хорошем качестве

Cancer Patient Perspectives Panel at 2019 CRI Immunotherapy Patient Summit in NYC

Three patients discuss their experiences with cancer immunotherapy: pembrolizumab (Keytruda) for stage 4 lung cancer, pembrolizumab (Keytruda) for advanced melanoma, and nivolumab (Opdivo) for stage 3 esophageal cancer. https://www.cancerresearch.org/summit #CRIsummit #immunotherapy Dorothy Fabian learned she had stage 3 esophageal cancer in March 2019 and enrolled in a clinical trial. Her family was vital to her decision-making and ensuring that she made her appointments and completed her treatments. Oswald Peterson received his first immunotherapy treatment in March 2017 for three months. Scans showed that cancer shrank dramatically after the second infusion. Oswald says immunotherapy is a "lifesaver." Tara Ryan shares her experience with advanced melanoma, which then spread to her brain. She was one of the early recipients of the newly approved drug, pembrolizumab (Keytruda). She describes the power of social media and community for support throughout her treatment and survivorship. Brian Brewer, director of marketing and communications at the Cancer Research Institute, moderated. The 2019 CRI Immunotherapy Summit in New York City was held at NYU Langone Health Perlmutter Cancer Center on September 7, 2019. Cancer Research Institute Immunotherapy Patient Summits are free half-day Saturday events that provide a forum for patients, caregivers, and advocates to meet together along with scientific and healthcare experts to learn more about how new breakthroughs in immunotherapy are changing standards of care for all cancers. Register at https://www.cancerresearch.org/summit The CRI Immunotherapy Patient Summit Series is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization that is dedicated to harnessing our immune system's power to control and potentially cure all cancers. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field's leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. Our Mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. https://www.cancerresearch.org